Legacy Health System
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Legacy Health System sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Legacy Health System: 21 sponsored US clinical trials, 1 recruiting.
Legacy Health System sponsors 21 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 14 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Retinopathy, with 1 trials.
Top-decile sponsor footprint
Legacy Health System ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
NCT07506876
Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking
NCT07328594
Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia
NCT04619719
Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy
NCT03916068
Effectiveness of High Dose Vitamin D Supplementation in Stage III Colorectal Cancer
NCT02603757
Artificial Pancreas Control System in an Outpatient Setting
NCT01871870
Preoperative Pain Control in Gastric Bypass Surgery Patients
NCT01801189
Artificial Pancreas Control System in an Inpatient Setting
NCT01552603
Physiologic Response to Glucagon at Varying Insulin Levels
NCT01483651
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
NCT01986231
Using the Optovue OCT to Select IOL Power
NCT01361282
Real-time Adaptation to Changes in Insulin Sensitivity
NCT01261052
Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy
NCT01006408
Continuous Glucose Monitoring to Measure Effect of Glycemic Index
NCT01145547
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
NCT00797823
Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients
NCT00419822
The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
NCT01364129
Determinants of Compliance With Glaucoma Therapy
NCT01484392
Hypertrophic Scarring After Facial Burn
NCT00242970
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
NCT00303615
The Significance of Sentinel Node Analysis in Colon Cancer
NCT00419978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Legacy Health System pipeline
1 recruiting of 21 indexed (5% open); 14 completed (67%).
Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Diabetic Retinopathy (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Legacy Health System: open-pipeline peers nationwide
Peers matched on 21 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Legacy Health System sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Cook County Health · 5% recruiting · 21 trials
- David Grant U.S. Air Force Medical Center · 5% recruiting · 21 trials
- Duquesne University · 5% recruiting · 21 trials
- Oregon Research Behavioral Intervention Strategies · 5% recruiting · 21 trials
Related
What to do with this Legacy Health System page
21 registered trials is a research-attention snapshot, not an endorsement of Legacy Health System or any single study.
- 1 of Legacy Health System's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetic Retinopathy is the condition Legacy Health System studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Retinopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Legacy Health System pipeline card: 21 registered trials from official public datasets.Report a data error.